I absolutely welcome balanced conversations here. But if you really want to have a balanced conversation, then how about we talk in logic. Do all cancer drugs have the ability to treat all types of cancers? Of course not. So you can't say "350 billion cancer and immunotherapy market" and "20 billion opioid market" and expect me to take that seriously.
Breast cancer, which is primarily what that other company's drug candidates are targeting, is nowhere near a 350 billion dollar market opportunity. In fact, breast cancer as an addressable segment/market appears to be much less than the opioid market already is. Is it growing quickly? Looks like it. Still a far cry from your original statement. Link:
Market Data 
Markets 
AI
